Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism.
OBJECTIVE
To evaluate selegiline, a monoamine oxidase-B inhibitor, for treating dogs with pituitary-dependent hyperadrenocorticism.


METHODS
Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at The University Veterinary Centre, Sydney, from September 1999 to July 2001.


METHODS
Eleven dogs with pituitary-dependent hyperadrenocorticism treated with selegiline were monitored at days 10, 30 and 90 by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and client questionnaire. Endogenous adrenocorticotropic hormone measurements were also performed on most dogs on days 0 and 90. No dog treated with selegiline had satisfactory control of disease.


CONCLUSIONS
Selegiline administration was safe and free of side-effects at the doses used, but did not satisfactorily control disease in pituitary-dependent hyperadrenocorticism affected dogs.
Braddock
J A
JA
Faculty of Veterinary Science, The University of Sydney, New South Wales 2006.
Church
D B
DB
Robertson
I D
ID
Watson
A D J
AD
D000284:Administration, Oral; D000304:Adrenal Cortex Function Tests / Q000662:veterinary; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D004285:Dogs; D005260:Female; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D012642:Selegiline / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D012642:Selegiline